Company / Working Capital per Share
Taysha Gene Therapies, Inc. Working Capital per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital per Share
$1.45
FY2025
5-year range
$0.62 / $2.86
FY2021-FY2025
Trend
+134.6%
vs FY2024
Sector context
#169 of 210
Health Care
What the data says
Taysha Gene Therapies, Inc.'s working capital per share of $1.45 is lower than 80% of companies in the Health Care sector (FY2025). Working Capital per Share has fluctuated over the past 6 years, ranging from $0.62 in FY2024 to $14.19 in FY2020.
Based on SEC 10-K filings.
1.45 in FY2025 with a 5-year CAGR of -36.6%.
Declined from $1.79 to $1.45 over the past 2 years.
Health Care sector context is included.
Working Capital per Share over time
Growth rates
- 3-Year CAGR
- +18.5%
- 5-Year CAGR
- -36.6%
- 10-Year CAGR
- -
Sector benchmark
-99.0% below sector average
Key checks
Key Insights
- In FY2025, working capital per share increased 134.6% year-over-year.
- Ranks #169 out of 210 companies in the Health Care sector.
- Peak working capital per share was recorded in FY2020.
- Lowest working capital per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working Capital per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.45 | +134.6% |
| FY2024 | $0.62 | -65.4% |
| FY2023 | $1.79 | +104.7% |
| FY2022 | $0.87 | -69.5% |
| FY2021 | $2.86 | -79.8% |
| FY2020 | $14.19 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026